Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR.
Latest News
Share this
News

TCT2018 Plans

Keystone Heart is excited to share with you our plans during TCT2018. TCT is the largest interventional cardiovascular medicine meeting focusing on education in the field of interventional and vascular medicine. This year it’s in sunny San Diego, CA!

In the spirit of TCT, Keystone Heart will educate attendees on the latest experience with TriGUARD 3™and our US Clinical Trial, REFLECT.

Our cornerstone event will be an educational lunch Symposium held on September 22nd. Our Chairs, Drs. Alexandra Lansky, Yale School of Medicine, and Tamim Nazif, Columbia University Medical Center, will lead a world-renown panel of physicians on this important clinical topic, including early US experience with TriGUARD 3.

Seating is limited and this event will fill quickly.

Please register here.

The Case for Complete Cerebral Embolic Protection –REFLECT
Saturday, September 22, 2018
Program: 1:00 pm-2:00 pm

If you have interest in meeting with Keystone Heart Executives during the week, please contact Dave Nevrla, Global Marketing Director, to schedule at dave.nevrla@keystoneheart.com.

TriGUARD 3 Cerebral Protection Device is for Investigational Use only and not commercially available.

 

 

 

Share

No Comments

Leave a reply